SICKLE CELL DISEASE | Alzheimer’s Drug Demonstrates Potential Therapeutic Benefit
New research published by the University of Zurich (UZH) sheds light on a promising and innovative approach to the management of sickle cell disease, one of the world’s most prevalent inherited blood disorders.
The study explores the potential of memantine, a medication that has been safely used for many years in the treatment of Alzheimer’s disease. Researchers investigated whether this well-known, affordable drug could also help reduce complications associated with sickle cell anemia. Findings from a Phase II clinical trial involving 17 patients indicate that memantine was well-tolerated, with no serious adverse effects observed during the course of treatment.
Importantly, participants receiving memantine experienced a reduction in the frequency and duration of hospitalizations, as well as fewer painful episodes, with particularly encouraging results reported among children. More than 25 laboratory parameters were monitored throughout the study, further confirming the drug’s long-term safety profile.
What makes this research especially significant is the potential global impact. Unlike high-cost interventions such as gene therapy or advanced biologics, memantine is inexpensive, widely available, and easy to store, making it a realistic option for low- and middle-income countries, where the burden of sickle cell disease remains disproportionately high.
The research team at UZH plans to continue this work through larger follow-up studies, including investigations of memantine both as a standalone therapy and in combination with established treatments such as hydroxyurea.
This study highlights the power of repurposing existing medicines to address unmet needs in rare and non-communicable diseases, offering renewed hope for improving the quality of life for people living with sickle cell anemia worldwide.
Source: University of Zurich
